Hanke lühikirjeldus
We have carried out a (high-throughput) screening of 30 000 low molecular substances against our target protein. One of the substances showed activity and selectivity on our target protein. After a silico-design, substances with 10 times high potency were found. We are not looking for a CRO that can help us with furthering development of our substances to improve pharmacology and toxicology properties.